# US 2017/0283400 A1 · Arginine methyltransferase inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283400 A1
- Document ID: US20170283400A1
- Status: Published application
- Kind: A1
- Application number: 15/511,523
- Filed: 2015-09-17
- Published: 2017-10-05
- Earliest claimed: 2014-09-17
- Assignees: Epizyme, Inc.
- Applicants: Epizyme, Inc.
- Inventors: Lorna Helen Mitchell; Kerren Kalai Swinger; Gideon Shapiro; Paula Ann Boriack-Sjodin
- Web page: https://patentgrep.com/patent/US20170283400A1

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are various compounds, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

## Claims

### Claim 1

A compound of Table 1, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 3 (depends on 1)

A kit or packaged pharmaceutical comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and instructions for use thereof.

### Claim 4 (depends on 1)

A method of inhibiting an arginine methyl tranferase (RMT) comprising contacting a cell with an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the arginine methyl transferase is PRMT1.

### Claim 6 (depends on 4)

The method of claim 4, wherein the arginine methyl transferase is PRMT6.

### Claim 7 (depends on 4)

The method of claim 4, wherein the arginine methyl transferase is PRMT8.

### Claim 8 (depends on 1)

A method of modulating gene expression comprising contacting a cell with an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

A method of modulating transcription comprising contacting a cell with an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 4, 5, 6, 7, 8, 9)

The method of any one of claims 4-9, wherein the cell is in vitro.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9)

The method of any one of claims 4-9, wherein the cell is in a subject.

### Claim 12 (depends on 1, 2)

A method of treating a RMT-mediated disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 2.

### Claim 13 (depends on 12)

The method of claim 12, wherein the RMT-mediated disorder is a PRMT1-mediated disorder.

### Claim 14 (depends on 12)

The method of claim 12, wherein the RMT-mediated disorder is a PRMT6-mediated disorder.

### Claim 15 (depends on 12)

The method of claim 12, wherein the RMT-mediated disorder is a PRMT8-mediated disorder.

### Claim 16 (depends on 12)

The method of claim 12, wherein the disorder is a proliferative disorder.

### Claim 17 (depends on 16)

The method of claim 16, wherein the proliferative disorder is cancer.

### Claim 18 (depends on 12)

The method of claim 12, wherein the disorder is a neurological disorder.

### Claim 19 (depends on 18)

The method of claim 18, wherein the neurological disorder is amyotrophic lateral sclerosis.

### Claim 20 (depends on 12)

The method of claim 12, wherein the disorder is a muscular dystrophy.

### Claim 21 (depends on 12)

The method of claim 12, wherein the disorder is an autoimmune disorder.

### Claim 22 (depends on 12)

The method of claim 12, wherein the disorder is a vascular disorder.

### Claim 23 (depends on 12)

The method of claim 12, wherein the disorder is a metabolic disorder.
